Company
Abacus Bioscience
First-in-Class Active Immunotherapies that overcome immune tolerance to treat cancer and chronic infection
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Legal name
- Abacus Bioscience
Claim, correct or request removal
Record updated 28 September 2026
About
Abacus Bioscience is developing a new class of targeted therapeutics to jump start the immune system, resulting in potent adaptive immunity specifically against cancer and infectious agents.
Funding snapshot
- Total raised
- $4.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $4.4M2023-01-19
Funding rounds
- Round, 2023
- $4.4M2023-01-19, SEC form D sold, 13 investors
Loading relationship preview